French cancer plan: a boost for personalized medicine and access to innovation
This article was originally published in SRA
The French pharmaceutical industry has welcomed the government's new National Cancer Plan for 2014-2019, which it says sends "a strong signal" in terms of the development of personalized medicine and accelerating patient access to innovative new anticancer therapies1,2.
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.